SHEA has joined with IDSA supporting inclusion of its proposed new antibacterial approval pathway within the FDA Prescription Drug User Fee Act (PDUFA) reauthorization legislation. In an April sent to the House Energy and Commerce Committee and Senate Education, Labor and Pensions Committee leaders, SHEA joins IDSA and other endorsing organizations to make the case that establishment of the Limited Population Antibacterial Drug (LPAD) approval mechanism will complement and significantly strengthen existing antibiotic provisions found in the House and Senate draft PDUFA bills.

View PDF (211 KB)